Pre-Exposure Prophylaxis for Transgender Women in the US and South America

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

307

Participants

Timeline

Start Date

March 26, 2021

Primary Completion Date

August 16, 2024

Study Completion Date

August 16, 2024

Conditions
HIV Prevention
Interventions
DRUG

Immediate Intervention Arm Truvada in the US

Truvada in the United States

DRUG

Deferred Intervention Arm Truvada in the US

Truvada in the United States

DRUG

Immediate Intervention Arm Truvada in Brazil

Truvada in Brazil

DRUG

Deferred Intervention Arm Truvada in Brazil

Truvada in Brazil

DRUG

Immediate Intervention Arm Descovy in the US

Descovy in the United States

DRUG

Deferred Intervention Arm Descovy in the US

Descovy in the United States

Trial Locations (5)

10027

Harlem Prevention Center CRS, New York

19104

Penn Prevention CRS, Philadelphia

77030

Houston AIDS Research Team CRS, Houston

94102

Bridge HIV CRS, San Francisco

221045-900

Instituto de Pesquisa Clinicaq Evandro Chagas CRS, Manguinhos

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Gilead Sciences

INDUSTRY

lead

HIV Prevention Trials Network

NETWORK

NCT04742491 - Pre-Exposure Prophylaxis for Transgender Women in the US and South America | Biotech Hunter | Biotech Hunter